Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Retatrutide 60mg | Research Compound
⭐ ⭐ ⭐ ⭐ ⭐ 4.9/104 Based on verified feedback
Consistent quality • Professional handling • Reliable delivery
🔴 HIGH DEMAND
$220.00
Retatrutide 60mg – Research Peptide
Triple Agonist Mechanism of Action (MOA)
Unlike single-target drugs Retatrutide acts like a "metabolic orchestra conductor" by simultaneously activating three major nutrient-sensing receptors:
GLP-1 (Glucagon-Like Peptide-1) Receptor Agonism: Stimulates insulin secretion in a glucose-dependent manner, delays gastric emptying (slowing digestion), and acts on the brain's hypothalamus to suppress appetite.
GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonism: Synergizes with GLP-1 to enhance insulin secretion, improves lipid (fat) buffering capability in adipose tissue, and crucially reduces the severity of nausea typically triggered by high-dose GLP-1 stimulation.
Glucagon Receptor Agonism: This is Retatrutide's unique edge. Glucagon normally raises blood sugar, but its hyper-glycemic effect is entirely neutralized by the co-activation of GLP-1 and GIP. Instead, glucagon safely drives weight loss by increasing energy expenditure (calories burned) and directly accelerating lipolysis (fat breakdown) in the liver.
3. Key Clinical Trial Insights
Data published across the Phase 2 and ongoing Phase 3 trials highlight unprecedented weight loss metrics:
Total Body Weight Loss
In Phase 3 data, participants on the highest weekly dose (12 mg) experienced a mean weight loss of up to 28% of their starting body weight over 68 to 80 weeks (an average of over 70 lbs). This makes it the most potent anti-obesity pharmacological agent tested to date.
The "Appetite Paradox" & Body Composition.
Because the glucagon pathway independently upregulates energy expenditure and fat-burning pathways, some patients experience massive fat loss even with a less suppressed appetite compared to older peptides. Furthermore, data indicates Retatrutide targets adipose tissue so precisely that it preserves crucial lean muscle mass exceptionally well during rapid weight loss.
Fatty Liver Reversal.
In Phase 2 sub-studies, Retatrutide achieved an astonishing 82% average reduction in liver fat, completely clearing non-alcoholic fatty liver disease (NAFLD/MASLD) in a majority of the trial participants
Product Details:
• Compound: Retatrutide
• Quantity: 60 mg
• Form: Lyophilized Powder
• Purity: ≥99% (if applicable)
• Storage: Store in a controlled laboratory environment, protected from light and moisture
Research Use Only
This product is intended strictly for laboratory research use only.
Not for human consumption.
Not for medical use.
Not intended to diagnose, treat, cure, or prevent any disease.
Not approved by the FDA.
This product is in powder form and is not reconstituted. All materials sold on this site are for laboratory research purposes only and are subject to our Terms and Conditions.
By purchasing, the buyer confirms this product will be used strictly for laboratory research purposes.
Retatrutide 60mg | Research Compound
⭐ ⭐ ⭐ ⭐ ⭐ 4.9/104 Based on verified feedback
Consistent quality • Professional handling • Reliable delivery
🔴 HIGH DEMAND
$220.00
Retatrutide 60mg – Research Peptide
Triple Agonist Mechanism of Action (MOA)
Unlike single-target drugs Retatrutide acts like a "metabolic orchestra conductor" by simultaneously activating three major nutrient-sensing receptors:
GLP-1 (Glucagon-Like Peptide-1) Receptor Agonism: Stimulates insulin secretion in a glucose-dependent manner, delays gastric emptying (slowing digestion), and acts on the brain's hypothalamus to suppress appetite.
GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonism: Synergizes with GLP-1 to enhance insulin secretion, improves lipid (fat) buffering capability in adipose tissue, and crucially reduces the severity of nausea typically triggered by high-dose GLP-1 stimulation.
Glucagon Receptor Agonism: This is Retatrutide's unique edge. Glucagon normally raises blood sugar, but its hyper-glycemic effect is entirely neutralized by the co-activation of GLP-1 and GIP. Instead, glucagon safely drives weight loss by increasing energy expenditure (calories burned) and directly accelerating lipolysis (fat breakdown) in the liver.
3. Key Clinical Trial Insights
Data published across the Phase 2 and ongoing Phase 3 trials highlight unprecedented weight loss metrics:
Total Body Weight Loss
In Phase 3 data, participants on the highest weekly dose (12 mg) experienced a mean weight loss of up to 28% of their starting body weight over 68 to 80 weeks (an average of over 70 lbs). This makes it the most potent anti-obesity pharmacological agent tested to date.
The "Appetite Paradox" & Body Composition.
Because the glucagon pathway independently upregulates energy expenditure and fat-burning pathways, some patients experience massive fat loss even with a less suppressed appetite compared to older peptides. Furthermore, data indicates Retatrutide targets adipose tissue so precisely that it preserves crucial lean muscle mass exceptionally well during rapid weight loss.
Fatty Liver Reversal.
In Phase 2 sub-studies, Retatrutide achieved an astonishing 82% average reduction in liver fat, completely clearing non-alcoholic fatty liver disease (NAFLD/MASLD) in a majority of the trial participants
Product Details:
• Compound: Retatrutide
• Quantity: 60 mg
• Form: Lyophilized Powder
• Purity: ≥99% (if applicable)
• Storage: Store in a controlled laboratory environment, protected from light and moisture
Research Use Only
This product is intended strictly for laboratory research use only.
Not for human consumption.
Not for medical use.
Not intended to diagnose, treat, cure, or prevent any disease.
Not approved by the FDA.
This product is in powder form and is not reconstituted. All materials sold on this site are for laboratory research purposes only and are subject to our Terms and Conditions.
By purchasing, the buyer confirms this product will be used strictly for laboratory research purposes.